34 results
8-K/A
EX-99.1
RNAC
Cartesian Therapeutics Inc
23 Jan 24
Independent Auditor’s Report
4:05pm
with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under
8-K
EX-99.3
RNAC
Cartesian Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
8:45am
are steadfast in our commitment to delivering meaningful new therapies to patients with autoimmune diseases in areas of high unmet need and look forward
DEFA14A
ldf5iw nnbv0b3
13 Nov 23
Additional proxy soliciting materials
9:06am
8-K
EX-99.2
r1k60mh9rlcckt8wvqj
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-10.1
a8lmv4ld4m0i dwmu
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-2.1
qxlh2f3i
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-3.2
flmelzw6pn23r iiuyg1
22 Aug 22
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
EX-99.1
d0yqdtr kdth0bups
13 Jun 22
Selecta Biosciences Announces Partnership Advancements
8:00am
DEFR14A
n5i1lx0
3 May 22
Revised proxy
2:15pm
PRE 14A
w2lybn
22 Apr 22
Preliminary proxy
3:08pm
8-K
EX-3.2
b7vk ebnh4v7p37ea0nu
30 Sep 21
Amendments to Articles of Incorporation or Bylaws
8:00am